Antihypertensive efficacy and safety of Olmesartan Medoxomil and Ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: A pooled post Hoc analysis of two comparative trials

Drugs and Aging

Volumn 29, Issue 12, 2012, Pages 981-992

  Omboni, Stefano ^a   Malacco, Ettore ^b   Mallion, Jean Michel ^c   Volpe, Massimo ^d  

^a ITALIAN INSTITUTE OF TELEMEDICINE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE; OLMESARTAN; PLACEBO; RAMIPRIL; ZOFENOPRIL;

ABDOMINAL PAIN; ADD ON THERAPY; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MILD ESSENTIAL HYPERTENSION; MODERATE ESSENTIAL HYPERTENSION; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SITTING; STOMACH PAIN; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; METABOLIC SYNDROME X; MONITORING, PHYSIOLOGIC; RAMIPRIL; SAFETY; TETRAZOLES;

EID: 84874597614     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-012-0030-3     Document Type: Article

References (45)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28. (Pubitemid 40523737)
2. Hu G, Qiao Q, Tuomilehto J, DECODE Study Group, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164:1066-76. (Pubitemid 38668985)
3. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28:2745-9. (Pubitemid 43951170)
4. Mannucci E, Monami M, Bardini G, et al. National Cholesterol Educational Program and International Diabetes Federation diagnostic criteria for metabolic syndrome in an Italian cohort: results from the FIBAR Study. J Endocrinol Invest. 2007;30:925-30. (Pubitemid 351350827)
5. Rueda Alfaro S, Serra-Prat M, Fernández Fernández C, et al. Estudio de Envejecimiento de Mataró. Metabolic syndrome and cardiovascular disease in elders: results of the Mataró Ageing study. Med Clin (Barc). 2008;130:327-31. (Pubitemid 351520623)
6. De Luis DA, Lopez Mongil R, Gonzalez Sagrado M, Group Novomet, et al. Prevalence of metabolic syndrome with International Diabetes Federation Criteria and ATP III Program in patients 65 years of age or older. J Nutr Health Aging. 2010;14:400-4.
7. Carlsson AC, Wändell PE, Halldin M, et al. Is a unified definition of metabolic syndrome needed? Comparison of three definitions of metabolic syndrome in 60-year-old men and women. Metab Syndr Relat Disord. 2009;7:231-41.
8. Hildrum B, Mykletun A, Hole T, et al. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health. 2007;7:220. (Pubitemid 350042945)
9. Gündogan K, Bayram F, Capak M, et al. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia. Metab Syndr Relat Disord. 2009;7:427-34.
10. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9. (Pubitemid 32893993)
11. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-16. (Pubitemid 35403784)
12. Hunt KJ, Resendez RG, Williams K, et al. San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110:1251-7. (Pubitemid 39202341)
13. Bonora E, Targher G, Formentini G, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med. 2004;21:52-8. (Pubitemid 38168029)
14. Després JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008;28:1039-49.
15. Mancia G, Bombelli M, Facchetti R, et al. Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events. J Hypertens. 2010;28:999-1006.
16. Wu SH, Liu Z, Ho SC. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur J Epidemiol. 2010;25:375-84.
17. Wang J, Ruotsalainen S, Moilanen L, et al. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J. 2007;28:857-64. (Pubitemid 47351113)
18. Wang J, Ruotsalainen S, Moilanen L, et al. The metabolic syndrome predicts incident stroke: a 14-year follow-up study in elderly people in Finland. Stroke. 2008;39:1078-83. (Pubitemid 351444669)
19. Vinluan CM, Zreikat HH, Levy JR, Cheang KI. Comparison of different metabolic syndrome definitions and risks of incident cardiovascular events in the elderly. Metabolism. 2012;61:302-9.
20. Kawano Y, Ogihara T, Saruta T, et al. Association of blood pressure control and metabolic syndrome with cardiovascular risk in elderly Japanese: JATOS Study. Am J Hypertens. 2011;24:1250-6.
21. Sharma AM, Engeli S. The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometab Syndr. 2006;1:29-35.
22. Cooper-DeHoff RM, Pepine CJ. Metabolic syndrome and cardiovascular disease: challenges and opportunities. Clin Cardiol. 2007;30:593-7. (Pubitemid 350293340)
23. Javed U, Deedwania PC. Angiotensin receptor blockers: novel role in high-risk patients. Cardiol Clin. 2008;26:507-26.
24. Mancia G, Laurent S, Agabiti-Rosei E, et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-58.
25. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008;68:1239-72. (Pubitemid 351822113)
26. Giles TD, Robinson TD. Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension. Am J Hypertens. 2004;17:690-5. (Pubitemid 39099176)
27. Mallion JM, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens. 2007;25:2168-77. (Pubitemid 47476316)
28. Heagerty AM, Mallion JM. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension: efficacy and safety data from clinical trials. Drugs Aging. 2009;26:61-76.
29. Malacco E, Omboni S, Volpe M, ESPORT Study Group, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. J Hypertens. 2010;28:2342-50.
30. Mallion JM, Omboni S, Barton J, Study Group, et al. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension. Blood Press. 2011;20(1 Suppl):3-11.
31. O'Brien E, Atkins N, Stergiou G, Working Group on Blood Pressure Monitoring of the European Society of Hypertension, et al. European Society of Hypertension International Protocol revision for the validation of blood pressure measuring devices in adults. Blood Press Monit. 2010;2010(15):23-38.
32. O'Brien E, Asmar R, Beilin L, European Society of Hypertension Working Group on Blood Pressure Monitoring, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21:821-48. (Pubitemid 36677141)
33. Alberti KG, Zimmet P, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-62. (Pubitemid 41338752)
34. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89:3A-9A.
35. Whaley-Connell A, Pavey BS, Chaudhary K, et al. Renin-angiotensin- aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. Ther Adv Cardiovasc Dis. 2007;1:27-35.
36. Anichkov DA, Shostak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin. 2005;21:113-9. (Pubitemid 40327512)
37. Shevchenko OP, PraskurnichiÄ EA, Savel'eva SA. Efficacy of combined antihypertensive treatment with amlodipine and lisinopril in metabolic syndrome. Ter Arkh. 2008;80:54-9.
38. KaÄdashev IP, Savchenko LH, KaÄdasheva EI, et al. Efficacy of complex therapy with metformin and ramipril combination for patients with metabolic syndrome. Lik Sprava. 2010;7-8:77-84.
39. Martinez-Martin FJ, Macias-Batista A, Comi-Diaz C, et al. Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. Clin Drug Investig. 2011;31:201-12.
40. Mancia G, Parati G, Bilo G, TALENT investigators, et al. Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study. J Hypertens. 2011;29:600-9.
41. Formosa V, Bellomo A, Iori A, et al. The treatment of hypertension with telmisartan in the sphere of circadian rhythm in metabolic syndrome in the elderly. Arch Gerontol Geriatr. 2009;49(1 Suppl.):95-101.
42. Black HR, Davis B, Barzilay J, et al. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2008;31:353-60. (Pubitemid 351213350)
43. Martinez-Martin FJ, Rodriguez-Rosas H, Peiro-Martinez I, et al. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens. 2011;25:346-53.
44. Chrysant SG, Lee J, Melino M, et al. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens. 2010;24:730-8.
45. Teramoto T, Fujita T, Kawamori R, et al. OMEGA study: design, baseline data, metabolic syndrome prevalence in a large-scale observational study of hypertensive patients: The Olmesartan Mega Study to Determine the Relationship between Cardiovascular Endpoints and Blood Pressure Goal Achievement study. Hypertens Res. 2008;31:2011-7.